Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BDTX with free AI briefings, catalyst countdowns, and dilution alerts.

BDTX · Black Diamond Therapeutics, Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$102M Cash on Hand
37.5mo Cash Runway
12% Short Interest
$10 Analyst Target (7)
Follow BDTX by email Get an email when BDTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BDTX, unsubscribe in one click. Privacy

📣 What BDTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Silevertinib Non-Small Cell Lung Cancer Phase 1/2 · NCT05256290 Active not recruiting
Use autologous cSVF + MSCs (cryo) for… Autism Spectrum Disorder Phase 1/2 · NCT07546942 Enrolling by invitation
Tuxobertinib (BDTX-189) Solid Tumor Phase 1 · NCT04209465 Terminated
Liberase Enzyme (Roche) Pulmonary Alveolar Proteinosis Early Phase 1 · NCT04326036 Unknown

Also used in these trials (approved or third-party drugs, not BDTX's own candidates): Temozolomide, Azathioprine, Carfilzomib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BDTX holds $102M in cash and short-term investments (as of Sep 30, 2026) and burns about $8.2M/quarter from operations, an estimated runway of 37.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 15 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BDTX files for a raise →

👥 Who Owns BDTX

Insiders 21.7% Institutions (153 holders) 72.7% Public and other holders 5.6%
HolderTypeShares% of sharesAs of
Ali Behbahani
Director · +101,100 options
Insider 4,558,993 7.93% 2026-09-18
Versant Venture Capital VI, L.P.
10% owner
Insider 4,548,481 7.91% 2024-08-28
NEA Management Company, LLC Institution (13F) 4,448,757 7.74% 2026-06-30
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 4,028,202 7.01% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 3,838,590 6.68% 2026-06-30
Growth N V Biotech
10% owner
Insider 2,733,547 4.76% 2025-03-19
Acadian Asset Management. LLC Institution (13F) 2,348,651 4.09% 2026-06-30
Vanguard Capital Management LLC Institution (13F) 2,125,270 3.70% 2026-06-30
Renaissance Technologies, LLC Institution (13F) 1,962,394 3.41% 2026-06-30
Defilade Capital Management, L.P. Institution (13F) 1,674,999 2.91% 2026-06-30
Dimensional Fund Advisors LP Institution (13F) 1,365,384 2.38% 2026-06-30
Geode Capital Management, LLC Institution (13F) 1,218,171 2.12% 2026-06-30

Share count 57,468,255 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-18
filed 2026-09-21
Raman Prakash
Award (A) 6,801 $1.93 51,840
2026-09-18
filed 2026-09-21
Behbahani Ali
Award (A) 7,707 $1.93 110,236
2026-06-19
filed 2026-06-22
Raman Prakash
Award (A) 7,907 $1.66 45,039
2026-06-19
filed 2026-06-22
Behbahani Ali
Award (A) 8,961 $1.66 102,529
2026-03-20
filed 2026-03-20
Raman Prakash
Award (A) 6,105 $2.15 37,132

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full BDTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BDTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.